SK278333B6 - Nucleic acid coding lymphotoxin - Google Patents

Nucleic acid coding lymphotoxin Download PDF

Info

Publication number
SK278333B6
SK278333B6 SK3930-85A SK393085A SK278333B6 SK 278333 B6 SK278333 B6 SK 278333B6 SK 393085 A SK393085 A SK 393085A SK 278333 B6 SK278333 B6 SK 278333B6
Authority
SK
Slovakia
Prior art keywords
lymphotoxin
variant
substituted
dna
sequence
Prior art date
Application number
SK3930-85A
Other languages
English (en)
Slovak (sk)
Other versions
SK393085A3 (en
Inventor
Bharat B Aggarwal
Timothy S Bringman
Patrick W Gray
Glenn E Nedwin
Original Assignee
Aggarwal Bharat B.
Bringman Timothy S.
Gray Patrick W.
Nedwin Glenn E.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US06/616,502 external-priority patent/US4959457A/en
Application filed by Aggarwal Bharat B., Bringman Timothy S., Gray Patrick W., Nedwin Glenn E. filed Critical Aggarwal Bharat B.
Publication of SK393085A3 publication Critical patent/SK393085A3/sk
Publication of SK278333B6 publication Critical patent/SK278333B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C07K16/242—Lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • C07K14/5255—Lymphotoxin [LT]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SK3930-85A 1984-05-31 1985-05-31 Nucleic acid coding lymphotoxin SK278333B6 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61650384A 1984-05-31 1984-05-31
US06/616,502 US4959457A (en) 1984-05-31 1984-05-31 Anti-lymphotoxin
US73231285A 1985-05-09 1985-05-09

Publications (2)

Publication Number Publication Date
SK393085A3 SK393085A3 (en) 1996-11-06
SK278333B6 true SK278333B6 (en) 1996-11-06

Family

ID=27417179

Family Applications (1)

Application Number Title Priority Date Filing Date
SK3930-85A SK278333B6 (en) 1984-05-31 1985-05-31 Nucleic acid coding lymphotoxin

Country Status (23)

Country Link
EP (2) EP0164965B1 (de)
JP (3) JP2521703B2 (de)
AR (1) AR245219A1 (de)
AT (2) ATE95243T1 (de)
AU (1) AU599303B2 (de)
BG (1) BG60256B1 (de)
CA (1) CA1340641C (de)
CZ (1) CZ283148B6 (de)
DE (2) DE3588225T2 (de)
DK (1) DK171531B1 (de)
ES (1) ES8802182A1 (de)
FI (1) FI93025C (de)
GR (1) GR851317B (de)
HU (1) HU204085B (de)
IE (1) IE63487B1 (de)
IL (1) IL75318A (de)
NO (1) NO179075C (de)
NZ (1) NZ212207A (de)
PL (1) PL155410B1 (de)
PT (1) PT80573B (de)
RO (1) RO100383A2 (de)
SK (1) SK278333B6 (de)
YU (1) YU47735B (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3177213D1 (de) 1980-04-03 1990-10-18 Biogen Inc Dns-sequenzen, rekombinante dns-molekuele und verfahren zur herstellung von dem menschlichen fibroblast-interferon.
NZ212207A (en) 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin
US5683688A (en) 1984-05-31 1997-11-04 Genentech, Inc. Unglycosylated recombinant human lymphotoxin polypeptides and compositions
IL73883A (en) * 1984-12-20 1990-12-23 Yeda Res & Dev Monoclonal antibodies against tnf-alpha,hybridomas producing them and method for the purification of tnf-alpha
EP0368367A1 (de) * 1984-12-21 1990-05-16 Biogen, Inc. Reinigung, Herstellung und Verwendung von Tumornekrosefaktoren
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin
JPS62195285A (ja) * 1986-02-19 1987-08-28 Kanegafuchi Chem Ind Co Ltd リンホトキシン発現ベクタ−及びそれを用いるリンホトキシンの製造方法
JPS62111928A (ja) * 1985-10-15 1987-05-22 Kanegafuchi Chem Ind Co Ltd 新規リンホトキシン
US5403725A (en) * 1985-12-24 1995-04-04 Denki Kagaku Kogyo Kabushiki Kaisha Method for production of lymphotoxin (TNFB) in cell line A-C5-8
JP2548204B2 (ja) * 1987-06-27 1996-10-30 電気化学工業株式会社 新生理活性ポリペプチド
EP0230781B1 (de) * 1985-12-24 1992-07-22 Denki Kagaku Kogyo Kabushiki Kaisha Lymphotoxin-Gen, Verfahren zu dessen Herstellung und Lymphotoxin
EP0230574A3 (de) * 1986-01-31 1989-03-22 Yale University Pharmazeutische Zusammensetzungen gegen durch LAV/HTLV-III-Virus verursachte Infektionen und ihre Verwendung
JPS62181298A (ja) * 1986-02-05 1987-08-08 Kyowa Hakko Kogyo Co Ltd ヒトリンホトキシンポリペプチド誘導体
DE3620656A1 (de) * 1986-06-20 1987-12-23 Basf Ag Polypeptide mit lymphotoxin-aktivitaet oder lymphotoxin-aehnlicher aktivitaet, ihre herstellung und verwendung
JPS63105680A (ja) * 1986-10-22 1988-05-10 Kanegafuchi Chem Ind Co Ltd ヒト・リンホトキシン発現ベクタ−、該発現ベクタ−による形質転換細胞および該細胞を用いるリンホトキシンの製造方法
JP2636862B2 (ja) * 1986-12-24 1997-07-30 武田薬品工業株式会社 組み換え型ヒトリンホトキシン
US5175268A (en) * 1986-12-24 1992-12-29 Takeda Chemical Industries, Ltd. DNA encoding recombinant human lymphotoxin
FI884798A (fi) * 1987-10-28 1989-04-29 Eisai Co Ltd Rekombinantlymfotoxin.
DE3837012A1 (de) * 1988-01-15 1989-07-27 Knoll Ag Verwendung von tnf und lt zur herstellung von arzneimitteln
GB2217326B (en) * 1988-04-08 1991-11-20 British Bio Technology Synthetic gene encoding human tumour necrosis factor beta.
EP0338497A3 (de) * 1988-04-22 1990-05-16 Takeda Chemical Industries, Ltd. Bispezifische hybride monoklonale Antikörper
JPH023698A (ja) * 1988-06-20 1990-01-09 Denki Kagaku Kogyo Kk ヒトリンホトキシンに対するモノクローナル抗体及びそれら抗体を産生するハイブリドーマ、並びにそれら抗体を用いたヒトリンホトキシンの精製方法、測定方法及び測定試薬
CA2001756A1 (en) * 1988-10-31 1991-04-30 Seiichi Uesugi New human lymphotoxin n-end deletion mutant
JPH03106821A (ja) * 1989-09-20 1991-05-07 Denki Kagaku Kogyo Kk 抗腫瘍剤
US5200176A (en) * 1989-10-06 1993-04-06 Genentech, Inc. Method for protection of ischemic tissues using tumor nerosis factor
US5370870A (en) * 1989-10-06 1994-12-06 Genentech, Inc. Method for protection against reactive oxygen species
IL97779A (en) * 1990-04-10 2000-01-31 Genentech Inc Compositions for cytoprotection against radiation and chemotherapy injury or risk thereof
US5747023A (en) * 1994-07-01 1998-05-05 Genentech, Inc. Cancer therapy using lymphotoxin
ES2179929T3 (es) * 1995-01-23 2003-02-01 Xenotech Inc Procedimiento que trata de inhibir la osteolisis y las metastasis.
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
JP2002508962A (ja) 1998-01-15 2002-03-26 ジェネンテク・インコーポレイテッド Ａｐｏ−２リガンド
EP2311870A1 (de) * 2002-11-26 2011-04-20 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung von Immunerkrankungen
US7700097B2 (en) 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
US20050266004A1 (en) * 2003-12-08 2005-12-01 Jill Giles-Komar Anti-human lymphotoxin alpha antibodies, compositions, methods and uses
JP2007530588A (ja) 2004-03-23 2007-11-01 バイオジェン・アイデック・エムエイ・インコーポレイテッド レセプターカップリング剤およびその治療用途
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
JP5298021B2 (ja) * 2006-10-12 2013-09-25 ジェネンテック， インコーポレイテッド リンホトキシン−αに対する抗体
CN101653599A (zh) 2006-10-20 2010-02-24 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
US8338376B2 (en) 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
WO2015164859A1 (en) * 2014-04-25 2015-10-29 Naurex, Inc. Stable compositions of neuroactive peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ192465A (en) * 1978-12-22 1983-09-30 Biogen Nv Recombinant dna molecule comprising gene coding for polypeptide displaying hbv (hepatitis b virus) antigenicity usesthereof
NZ201918A (en) 1981-09-18 1987-04-30 Genentech Inc N-terminal methionyl analogues of bovine growth hormone
ZA834976B (en) * 1982-07-30 1984-08-29 Genentech Inc Human lymphotoxin
FI82266C (fi) * 1982-10-19 1991-02-11 Cetus Corp Foerfarande foer framstaellning av il-2 -mutein.
DE3331108A1 (de) * 1983-08-30 1985-05-02 Boehringer Ingelheim International GmbH, 6507 Ingelheim Verfahren zur herstellung von lymphotoxin und von lymphotoxin-mrna
EP0135797A3 (de) * 1983-08-30 1987-11-11 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Verfahren zur Herstellung von Lymphotoxin und von Lymphotoxin-mRNA
NZ212207A (en) 1984-05-31 1991-07-26 Genentech Inc Recombinant lymphotoxin

Also Published As

Publication number Publication date
IE930589L (en) 1985-11-30
NO852173L (no) 1985-12-02
DE3588225T2 (de) 2001-04-05
HUT37814A (en) 1986-02-28
DK171531B1 (da) 1996-12-23
ES8802182A1 (es) 1988-04-16
CZ283148B6 (cs) 1998-01-14
ATE95243T1 (de) 1993-10-15
GR851317B (de) 1985-11-25
SK393085A3 (en) 1996-11-06
DK241385A (da) 1985-12-01
DE3587597D1 (de) 1993-11-04
AR245219A1 (es) 1993-12-30
DK241385D0 (da) 1985-05-30
CZ393085A3 (en) 1997-07-16
NO179075C (no) 1996-07-31
YU91985A (en) 1988-12-31
ATE195323T1 (de) 2000-08-15
HU204085B (en) 1991-11-28
CA1340641C (en) 1999-07-13
EP0509553A1 (de) 1992-10-21
JPS6156197A (ja) 1986-03-20
IE851321L (en) 1985-11-30
AU599303B2 (en) 1990-07-19
RO100383A2 (ro) 1991-10-17
FI93025B (fi) 1994-10-31
JPH07291995A (ja) 1995-11-07
PT80573A (en) 1985-06-01
RO100383B1 (ro) 1991-03-01
FI852143A0 (fi) 1985-05-29
BG60256B2 (bg) 1994-03-24
JPH07250692A (ja) 1995-10-03
NO179075B (no) 1996-04-22
EP0164965A2 (de) 1985-12-18
PL253739A1 (en) 1986-03-11
IL75318A (en) 1994-08-26
DE3588225D1 (de) 2000-09-14
JP2804237B2 (ja) 1998-09-24
JP2521703B2 (ja) 1996-08-07
YU47735B (sh) 1996-01-08
EP0164965A3 (en) 1988-04-06
FI852143L (fi) 1985-12-01
EP0509553B1 (de) 2000-08-09
PT80573B (pt) 1987-08-19
FI93025C (fi) 1995-02-10
EP0164965B1 (de) 1993-09-29
AU4320385A (en) 1985-12-05
BG60256B1 (bg) 1994-03-24
NZ212207A (en) 1991-07-26
PL155410B1 (en) 1991-11-29
IL75318A0 (en) 1985-09-29
DE3587597T2 (de) 1994-06-01
ES543695A0 (es) 1988-04-16
IE63487B1 (en) 1995-05-03

Similar Documents

Publication Publication Date Title
SK278333B6 (en) Nucleic acid coding lymphotoxin
JP2614989B2 (ja) 腫瘍壊死因子含有組成物
Sheehan et al. Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors.
US4650674A (en) Synergistic cytotoxic composition
US5475087A (en) Antagonists of human granulocyte-macrophage colony stimulating factor derived from the carboxyl terminus
US5683688A (en) Unglycosylated recombinant human lymphotoxin polypeptides and compositions
US4959457A (en) Anti-lymphotoxin
IL104297A (en) Lymphotoxin Nucleic acid encoding vectors containing the nucleic acid and cells converted by them Methods for obtaining lymphotoxin
DK172382B1 (da) Rekombinante lymphotoxinderivater
NZ226980A (en) Lymphotoxin-neutralising antibody and its use in separating out lymphotoxin from a composition
US6686455B1 (en) Tumor necrosis factor
PT80758B (pt) Metodo para a preparacao de factor de necrose tumoral